Common genetic aspects between polycystic ovary syndrome and diabetes mellitus

Current Diabetes Reviews

Volumn 7, Issue 6, 2011, Pages 377-391

  Mendoza, Nicolás ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Insulin resistance; Polycystic ovary syndrome; Polymorphism

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADIPONECTIN; ALDOSTERONE SYNTHASE; ANDROGEN RECEPTOR; APOLIPOPROTEIN E; AROMATASE; BONE MORPHOGENETIC PROTEIN; CALPAIN 10; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450 1A1; DOPAMINE 3 RECEPTOR; ESTROGEN RECEPTOR ALPHA; FATTY ACID BINDING PROTEIN 4; FOLLISTATIN; FOLLITROPIN; FOLLITROPIN RECEPTOR BINDING INHIBITOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; GROWTH DIFFERENTIATION FACTOR 9; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; LEPTIN; LEPTIN RECEPTOR; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; STEROID 17ALPHA MONOOXYGENASE; STEROID 21 MONOOXYGENASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; UNINDEXED DRUG;

ARTICLE; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; DIET; FEMALE; FEMALE FERTILITY; HEREDITY; HUMAN; HYPERANDROGENISM; LIPID METABOLISM; MENSTRUATION DISORDER; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; HYPERANDROGENISM; INFERTILITY; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 80054069932     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339911797579142     Document Type: Article

References (210)

1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003, consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
2. Pasquali R, Stener-Victorin E, Yildiz BO, Duleba AJ, Hoeger K, Mason H, Homburg R, Hickey T, Franks S, Tapanainen JS, Balen A, Abbott DH, Diamanti-Kandarakis E, Legro RS. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol (Oxf) 2011; 74: 424-33.
3. Simoni M, Tempfer CB, Destenaves B, Fauser BC. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Hum Reprod Update 2008; 14: 459-84.
4. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet 2011; 43: 55-9.
5. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A 1998; 95: 14956-60.
6. Govind A., Obhrai M, Clayton R. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 1999; 84: 38-43.
7. Diao F, Xu M, Hu Y. The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray. J Mol Endocrinol 2004; 33: 59-72.
8. Wood JR, Dumesic DA, Abbott DH. Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis. J Clin Endocrinol Metab 2007; 92: 705-13.
9. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997; 6: 397-402.
10. Dasgupta S, Sirisha PV, Neelaveni K, et al. Androgen receptor CAG repeat polymorphism and epigenetic influence among the south Indian women with Polycystic Ovary Syndrome. PLoS One 2010; 5: e12401.
11. Kevenaar ME, Themmen AP, van Kerkwijk AJ, et al. Variants in the ACVR1 gene are associated with AMH levels in women with polycystic ovary syndrome. Hum Reprod 2009; 24: 241-9.
12. Kurabayashi T, Yahata T, Quan J, Tanaka K. Association of polymorphisms in the beta2 and beta3 adrenoceptor gene with polycystic ovary syndrome. J Reprod Med 2006; 51: 389-93.
13. Perez-Bravo F, Echiburu B, Maliqueo M, Santos JL, Sir-Petermann T. Tryptophan 64 -> arginine polymorphism of beta-3-adrenergic receptor in Chilean women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 62: 126-31.
14. Kevenaar ME, Themmen AP, Laven JS, et al. Anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normoovulatory women. Hum Reprod. 2007; 22: 1547-54.
15. Jones MR, Mathur R, Cui J, Guo X, Azziz R, Goodarzi MO. Independent confirmation of association between metabolic phenotypes of polycystic ovary syndrome and variation in the type 6 17betahydroxysteroid dehydrogenase gene. J Clin Endocrinol Metab 2009; 94(12): 5034-8.
16. Qin K, Ehrmann DA, Cox N, Refetoff S, Rosenfield RL. Identification of a functional polymorphism of the human type 5 17betahydroxysteroid dehydrogenase gene associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 270-6.
17. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab 2000; 85: 3484-8.
18. Tong D, Deng J, Sun H, Chen L, Wu X. The relationship between CAG repeat length polymorphism and infertility in Southern Chinese Han women. J Endocrinol Invest 2010; 33: 559-63.
19. Laisk T, Haller-Kikkatalo K, Laanpere M, et al. Androgen receptor epigenetic variations influence early follicular phase gonadotropin levels. Acta Obstet Gynecol Scand 2010; 89: 1557-63.
20. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 161-5.
21. Jaaskelainen J, Korhonen S, Voutilainen R, Hippelainen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. Fertil Steril 2005; 83: 1724-8.
22. Gao GH, Cao YX, Yi L, Wei ZL, Xu YP, Yang C. [Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. Zhonghua Fu Chan Ke Za Zhi 2010; 45: 191-6.
23. Peng CY, Long XY, Lu GX. Association of AR rs6152G/A gene polymorphism with susceptibility to polycystic ovary syndrome in Chinese women. Reprod Fertil Dev 2010; 22: 881-5.
24. Moron FJ, de Castro F, Royo JL, et al. Bone morphogenetic protein 15 (BMP15) alleles predict over-response to recombinant follicle stimulation hormone and iatrogenic ovarian hyperstimulation syndrome (OHSS) Pharmacogenet Genomics 2006; 16: 485-95.
25. Gónzalez A, Ramírez-Lorca R, Calatayud C, et al. Association of genetic markers within the BMP15 gene with anovulation and infertility in women with polycystic ovary syndrome. Fertil Steril 2008; 90: 447-9.
26. Babu KA, Rao KL, Kanakavalli MK, Suryanarayana VV, Deenadayal M, Singh L. CYP1A1, GSTM1 and GSTT1 genetic polymorphism is associated with susceptibility to polycystic ovaries in South Indian women. Reprod Biomed Online 2004; 9: 194-200.
27. Akgül S, Derman O, Alikaşifoǧlu M, Aktaş D. CYP1A1 polymorphism in adolescents with polycystic ovary syndrome. Int J Gynaecol Obstet 2011; 112: 8-10.
28. Unsal T, Konac E, Yesilkaya E, et al. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. J Assist Reprod Genet 2009; 26: 205-16.
29. Wang B, Wang J, Liu J, et al. Lack of an association between CYP1A1 gene Ile462Val polymorphism and polycystic ovary syndrome in Chinese. Endocrine 2009; 36: 16-9.
30. Diamanti-Kandarakis E Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta)(n) at -528 base pairs of gene CYP11alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000; 73: 735-41.
31. Gaasenbeek M, Powell BL, Sovio U, et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clin Endocrinol Metab 2004; 89: 2408-2413.
32. Wang Y, Wu X, Cao Y, Yi L, Chen J. A microsatellite polymorphism (tttta)n in the promoter of the CYP11a gene in Chinese women with polycystic ovary syndrome. Fertil Steril 2006; 86: 223-6.
33. Prazáková S, Vanková M, Bradnová O, et al. [(TTTTA), polymorphism in the promoter of the CYP11A1 gene in the pathogenesis of polycystic ovary syndrome]. Cas Lek Cesk 2010; 149: 520-5.
34. Zhao SP, Tang XM, Shao DH, Dai HY, Dai SZ. Association study between a polymorphism of aldosterone synthetase gene and the pathogenesis of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2003; 38: 94-7.
35. Park JM, Lee EJ, Ramakrishna S, Cha DH, Baek KH. Association study for single nucleotide polymorphisms in the CYP17A1 gene and polycystic ovary syndrome. Int J Mol Med 2008; 22: 249-54.
36. Marszalek B, Lacinski M, Babych N, et al. Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5́- UTR in patients with polycystic ovarian syndrome. Gynecol Endocrinol 2001; 15: 123-8.
37. Diamanti-Kandarakis E, Bartzis MI, Zapanti ED, et al. Polymorphism T->C (-34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome. Fertil Steril 1999; 71: 431-5.
38. Techatraisak K, Conway GS, Rumsby G. Frequency of a polymorphism in the regulatory region of the 17 alpha-hydroxylase-17,20- lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol (Oxf) 1997; 46: 131-134.
39. Petry CJ, Ong KK, Michelmore KF, et al. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005; 20: 1837-43.
40. Hao CF, Zhang N, Qu Q, Wang X, Gu HF, Chen ZJ. Evaluation of the association between the CYP19 Tetranucleotide (TTTA)n polymorphism and polycystic ovarian syndrome(PCOS) in Han Chinese women. Neuro Endocrinol Lett 2010; 31: 370-4.
41. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. CYP19 gene: a genetic modifier of polycystic ovary syndrome phenotype. Fertil Steril 2010; 94: 250-4.
42. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997; 6: 397-402.
43. Hao CF, Bao HC, Zhang N, Gu HF, Chen ZJ. Evaluation of association between the CYP11alpha promoter pentannucleotide (TTTTA)n polymorphism and polycystic ovarian syndrome among Han Chinese women. Neuro Endocrinol Lett 2009; 30: 56-60.
44. Jin JL, Sun J, Ge HJ, et al. Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. BMC Med Genet 2009; 10: 139.
45. Wang H, Li Q, Wang T, et al. A common polymorphism in the human aromatase gene alters the risk for polycystic ovary syndrome and modifies aromatase activity in vitro. Mol Hum Reprod 2011; 17: 386-91.
46. de Castro F, Moron FJ, Montoro L, et al. Human controlled ovarian hyperstimulation outcome is a polygenic trait. Pharmacogenetics 2004; 14: 285-93.
47. Pucci L, Lucchesi D, Longo V, Del Prato S, Maffei S. Lack of association between CYP21 V281L variant and polycystic ovary syndrome in Italian women. Gynecol Endocrinol 2010; 26: 596-9.
48. Kahsar-Miller M, Boots LR, Azziz R. Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome. Fertil Steril. 1999; 71: 436-8.
49. Korhonen S, Romppanen EL, Hiltunen M, et al. Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are associated with polycystic ovary syndrome. Fertil Steril 2003; 79: 1353-7.
50. Kim JJ, Choi YM, Choung SH, Yoon SH, Lee GH, Moon SY. Estrogen receptor beta gene +1730 G/A polymorphism in women with polycystic ovary syndrome. Fertil Steril 2010; 93: 1942-7.
51. Ewens KG, Stewart DR, Ankener W, et al. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab 2010; 5: 2306-15.
52. Goodarzi MO, Maher JF, Cui J, Guo X, Taylor KD, Azziz R. FEM1A and FEM1B: novel candidate genes for polycystic ovary syndrome. Hum Reprod 2008; 3: 2842-9.
53. Tong Y, Liao WX, Roy AC, Ng SC. Association of AccI polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome. Fertil Steril 2000; 74: 1233-6.
54. Sudo S, Kudo M, Wada S, Sato O, Hsueh AJ, Fujimoto S. Genetic and functional analyses of polymorphisms in the human FSH receptor gene. Mol Hum Reprod 2002; 8: 893-9.
55. Du J, Zhang W, Guo L, et al. Two FSHR variants, haplotypes and meta-analysis in Chinese women with premature ovarian failure and polycystic ovary syndrome. Mol Genet Metab 2010; 100: 292-295.
56. Tong Y, Liao WX, Roy AC, Ng SC. Absence of mutations in the coding regions of follicle-stimulating hormone receptor gene in Singapore Chinese women with premature ovarian failure and polycystic ovary syndrome. Horm Metab Res 2001; 33: 221-6.
57. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J, Simoni M. Mutation screening and isoform prevalence of the follicle stimulating hormone receptor gene in women with premature ovarian failure, resistant ovary syndrome and polycystic ovary syndrome. Clin Endocrinol (Oxf) 1999; 51: 97-99.
58. Gu BH, Park JM, Baek KH. Genetic variations of follicle stimulating hormone receptor are associated with polycystic ovary syndrome. Int J Mol Med 2010; 26: 107-112.
59. de Castro F, Ruiz R, Montoro L, et al. Role of follicle-stimulating hormone receptor Ser680Asn polymorphism in the efficacy of follicle-stimulating hormone. Fertil Steril 2003; 80: 571-576.
60. Loutradis D, Patsoula E, Minas V, et al. FSH receptor gene polymorphisms have a role for different ovarian response to stimulation in patients entering IVF/ICSI-ET programs. J Assist Reprod Genet 2006; 23: 177-184.
61. Behre HM, Greb RR, Mempel A, et al. Significance of a common single nucleotide polymorphism in exon 10 of the folliclestimulating hormone (FSH) receptor gene for the ovarian response to FSH: a pharmacogenetic approach to controlled ovarian hyperstimulation. Pharmacogenet Genomics 2005; 15: 451-456.
62. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M. Ovarian response to follicle-stimulating hormone (FSH) stimulation depends on the FSH receptor genotype. J Clin Endocrinol Metab 2000; 85: 3365-3369.
63. Jun JK, Yoon JS, Ku SY, et al. Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVF-ET. J Hum Genet 2006; 51: 665-70.
64. Valkenburg O, Uitterlinden AG, Piersma D, et al. Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. Hum Reprod 2009; 24: 2014-2022.
65. Klinkert ER, te Velde ER, Weima S, et al. FSH receptor genotype is associated with pregnancy but not with ovarian response in IVF. Reprod Biomed Online 2006; 13: 687-95.
66. Calvo RM, Villuendas G, Sancho J, San Millan JL, Escobar-Morreale HF. Role of the follistatin gene in women with polycystic ovary syndrome. Fertil Steril 2001; 75: 1020-3.
67. Urbanek M, Wu X, Vickery KR, et al. Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 4455-61.
68. Jones MR, Wilson SG, Mullin BH, Mead R, Watts GF, Stuckey BG. Polymorphism of the follistatin gene in polycystic ovary syndrome. Mol Hum Reprod 2007; 13: 237-41.
69. Jones MR, Italiano L, Wilson SG, et al. Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. Fertil Steril 2006; 86: 1438-46.
70. Wang B, Zhou S, Wang J, et al. Identification of novel missense mutations of GDF9 in Chinese women with polycystic ovary syndrome. Reprod Biomed Online 2010; 21: 344-8.
71. Hahn S, Frey UH, Siffert W, Tan S, Mann K, Janssen OE. The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. Eur J Endocrinol 2006; 155:763-70.
72. San Millan JL, Botella-Carretero JI, Alvarez-Blasco F, et al. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin lymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 4157-62.
73. Draper N, Powell BL, Franks S, Conway GS, Stewart PM, McCarthy MI. Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65: 64-70.
74. Qin K, Rosenfield RL. Mutations of the hexose-6-phosphate dehydrogenase gene rarely cause hyperandrogenemic polycystic ovary syndrome. Steroids 2011; 76: 135-9.
75. Marioli DJ, Saltamavros AD, Vervita V, et al. Association of the 17-hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) with hyperandrogenemia in polycystic ovary syndrome (PCOS). Fertil Steril 2009; 92: 648-52.
76. Ke L, Che YN, Cao YX, et al. Polymorphisms of the HSD17B6 and HSD17B5 genes in Chinese women with polycystic ovary syndrome. J Womens Health (Larchmt) 2010; 19: 2227-32.
77. Yang Y, Qiao J, Li MZ. Association of polymorphisms of interleukin- 18 gene promoter region with polycystic ovary syndrome in chinese population. Reprod Biol Endocrinol 2010; 8: 125.
78. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen S, Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod 2000; 6: 873-6.
79. Erel CT, Cine N, Elter K, Kaleli S. Leptin receptor variant in women with polycystic ovary syndrome. Fertil Steril 2002; 78: 1334-5.
80. Elter K, Erel CT, Cine N, Ozbek U, Hacihanefioglu B, Ertungealp E. Role of the mutations Trp8=> Arg and Ile15=> Thr of the human luteinizing hormone beta-subunit in women with polycystic ovary syndrome. Fertil Steril 1999; 71: 425-30.
81. Rajkhowa M, Talbot JA, Jones PW, et al. Prevalence of an immunological LH beta-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1995; 43: 297-303.
82. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormonebinding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003; 88: 5976-80.
83. Ferk P, Teran N, Gersak K. The (TAAAA)n microsatellite polymorphism in the SHBG gene influences serum SHBG levels in women with polycystic ovary syndrome. Hum Reprod 2007; 22: 1031-6.
84. Bendlova B, Zavadilova J, Vankova M, et al. Role of D327N sex hormone-binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome. J Steroid Biochem Mol Biol 2007; 104: 68-74.
85. Chen C, Wickenheisser J, Ewens KG, et al. PDE8A genetic variation, polycystic ovary syndrome and androgen levels in women. Mol Hum Reprod 2009; 15: 459-69.
86. Goodarzi MO, Shah NA, Antoine HJ, Pall M, Guo X, Azziz R. Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J Clin Endocrinol Metab 2006; 91: 4085-91.
87. Graupp M, Wehr E, Schweighofer N, Pieber TR, Obermayer-Pietsch B. Association of genetic variants in the two isoforms of 5́-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2011; 157: 175-179.
88. Haap M, Machicao F, Stefan N, et al. Genetic determinants of insulin action in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2005; 113: 275-81.
89. Heinonen S, Korhonen S, Helisalmi S, et al. Associations between two single nucleotide polymorphisms in the adiponectin gene and polycystic ovary syndrome. Gynecol Endocrinol 2005; 21: 165-9.
90. Zhang N, Shi YH, Hao C, Gu HF, Li Y, Zhao Y. Association 117. of C45G15G(T/G) and C276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol 2008; 158: 255-60.
91. Panidis D, Kourtis A, Kukuvitis A, et al. Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Delta4-androstenedione. Hum Reprod 2004; 19: 1728-33.
92. Xita N, Georgiou I, Chatzikyriakidou A, et al. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem 2005; 51: 416-23.
93. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004; 89: 2640-6.
94. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI. Álvarez-Blasco F, Sanchón R, Luque-Ramírez M. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod 2006; 21: 2257-65.
95. Li L, Yun JH, Lee JH, Song S, Choi BC, Baek KH. Association study of +45G15G(T/G) and +276(G/T) polymorphisms in the adiponectin gene in patients with polycystic ovary syndrome. Int J Mol Med 2011; 27: 283-7.
96. Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. Gynecol Endocrinol 2010; 26: 348-55.
97. Yoshihara K, Yahata T, Kashima K, Mikami T, Tanaka K. Association of single nucleotide polymorphisms in adiponectin and its receptor genes with polycystic ovary syndrome. J Reprod Med 2009; 54: 669-74.
98. Baba T, Endo T, Sata F, et al. The contributions of resistin and adiponectin gene single nucleotide polymorphisms to the genetic risk for polycystic ovary syndrome in a Japanese population. Gynecol Endocrinol 2009; 25: 498-503.
99. Heinonen S, Korhonen S, Hippelainen M, Hiltunen M, Mannermaa A, Saarikoski S. Apolipoprotein E alleles in women with polycystic ovary syndrome. Fertil Steril 2001; 75: 878-80.
100. Gonzalez A, Abril E, Roca A, et al. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 2003; 88: 5529-36.
101. Márquez JL, Pacheco A, Valdés P, Salazar LA. Association between CAPN10 UCSNP-43 gene polymorphism and polycystic ovary syndrome in Chilean women. Clin Chim Acta 2008; 398: 5-9.
102. Yilmaz M, Yurtçu E, Demirci H, et al. Calpain 10 gene singlenucleotide 44 polymorphism may have an influence on clinical and metabolic features in patients with polycystic ovary syndrome. J Endocrinol Invest 2009; 32: 13-17.
103. Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S. Variation within the type 2 diabetes susceptibility gene calpain- 10 and polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 2606-10.
104. Escobar-Morreale HF, Peral B, Villuendas G, Calvo RM, Sancho J, San Millan JL. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil Steril 2002; 77: 581-7.
105. Vollmert C, Hahn S, Lamina C, et al. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians. Am J Physiol Endocrinol Metab 2007; 292: E836-44.
106. Ehrmann DA, Schwarz PE, Hara M, et al. Relationship of calpain- 10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 1669-73.
107. Lee JY, Lee WJ, Hur SE, Lee CM, Sung YA, Chung HW. 111/121 diplotype of calpain-10 is associated with the risk of polycystic ovary syndrome in Korean women. Fertil Steril 2009; 92: 830-3.
108. Heinonen S, Korhonen S, Helisalmi S, Koivunen R, Tapanainen JS, Laakso M. The 121Q allele of the plasma cell membrane glycoprotein 1 gene predisposes to polycystic ovary syndrome. Fertil Steril 2004; 82: 743-5.
109. Shi Y, Sun X, Chen Z, Zhang P, Zhao Y, You L. Association 99. of the polymorphism of codon 121 in the ecto-nucleotide pyrophosphatase/ phosphodiesterase 1 gene with polycystic ovary syndrome in Chinese women. Saudi Med J 2008; 29: 1119-23.
110. Baba T, Endo T, Sata F, et al. Polycystic ovary syndrome is associated with genetic polymorphism in the insulin signaling gene IRS-1 but not ENPP1 in a Japanese population. Life Sci 2007; 81: 850-4.
111. Lin S, Huiya Z, Bo L, Wei W, Yongmei G. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome. Endocrine 2009; 36: 503-9.
112. Tan S, Scherag A, Janssen OE, et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 2010; 11: 12.
113. Wehr E, Schweighofer N, Möller R, Giuliani A, Pieber TR, Obermayer-Pietsch B. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010; 59: 575-80.
114. Attaoua R, Ait El Mkadem S, Radian S, et al. FTO gene associates to metabolic syndrome in women with polycystic ovary syndrome. Biochem Biophys Res Commun 2008; 373: 230-4.
115. Yan Q, Hong J, Gu W, et al. Association of the common rs9939609 variant of FTO gene with polycystic ovary syndrome in Chinese women. Endocrine 2009; 36: 377-82.
116. Klenke S, Tan S, Hahn S, et al. A functional GNAQ promoter haplotype is associated with altered Gq expression and with insulin resistance and obesity in women with polycystic ovary syndrome. Pharmacogenet Genomics 2010; 20: 476-84.
117. Rajkhowa M, Talbot JA, Jones PW, Clayton RN. Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996; 44: 85-90.
118. Alvarez-Blasco F, Martínez-García MA, Luque-Ramírez M, Parraza N, San Millán JL, Escobar-Morreale HF. Role of haptoglobin in polycystic ovary syndrome (PCOS), obesity and disorders of glucose tolerance in premenopausal women. PLoS One 2009; 4:e5606.
119. Franks S, Gharani N, McCarthy M. Genetic abnormalities in polycystic ovary syndrome. Ann Endocrinol (Paris) 1999; 60: 131-3.
120. Michelmore K, Ong K, Mason S, et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol (Oxf) 2001; 55: 439-46.
121. Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997; 349: 986-990.
122. Powell BL, Haddad L, Bennett A, et al. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab 2005; 90: 2988-2993.
123. Calvo RM, Telleria D, Sancho J, San Millan JL, Escobar-Morreale HF. Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril 2002; 77: 666-668.
124. Vankova M, Vrbikova J, Hill M, Cinek O, Bendlova B. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. Ann N Y Acad Sci 2002; 967: 558-65.
125. Xu Y, Wei Z, Zhang Z, et al. No association of the insulin gene VNTR polymorphism with polycystic ovary syndrome in a Han Chinese population. Reprod Biol Endocrinol 2009; 7:141.
126. Chen ZJ, Shi YH, Zhao YR, et al. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 2004; 39: 582-5.
127. Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 2002; 78: 1240-1243.
128. Lee EJ, Yoo KJ, Kim SJ, Lee SH, Cha KY, Baek KH. Single nucleotide polymorphism in exon 17 of the insulin receptor gene is not associated with polycystic ovary syndrome in a Korean population. Fertil Steril 2006; 86: 380-384.
129. Jin L, Zhu XM, Luo Q, Qian Y, Jin F, Huang HF. A novel 82. SNP at exon 17 of INSR is associated with decreased insulin sensitivity in Chinese women with PCOS. Mol Hum Reprod 2006; 12: 151-155.
130. Goodarzi MO, Louwers YV, Taylor KD, et al. Replication of association of a novel insulin receptor gene polymorphism with polycystic ovary syndrome. Fertil Steril 2011; 95: 1736-1741.
131. Lee EJ, Oh B, Lee JY, Kimm K, Lee SH, Baek KH. A novel single nucleotide polymorphism of INSR gene for polycystic ovary syndrome. Fertil Steril 2008; 89: 1213-1220.
132. Tucci S, Futterweit W, Concepcion ES, Greenberg DA. Villanueva R, Davies TF. Evidence for association of polycystic ovary syndrome in caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001; 86: 446-449.
133. Villuendas G, Escobar-Morreale HF, Tosi F, Sancho J. Moghetti P, San Millan JL. Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome. Fertil Steril 2003; 79: 219-220.
134. Mukherjee S, Shaikh N, Khavale S, Shinde G, Meherji P, Shah N. Genetic variation in exon 17 of INSR is associated with insulin resistance and hyperandrogenemia among lean Indian women with polycystic ovary syndrome. Eur J Endocrinol 2009; 160: 855-62.
135. Hanzu FA, Radian S, Attaoua R, et al. Association of insulin receptor genetic variants with polycystic ovary syndrome in a population of women from Central Europe. Fertil Steril 2010; 94: 2389-92.
136. Sir-Petermann T, Angel B, Maliqueo M, et al. Insulin secretion in women who have polycystic ovary syndrome and carry the Gly972Arg variant of insulin receptor substrate-1 in response to a high-glycemic or low-glycemic carbohydrate load. Nutrition 2004; 20: 905-10.
137. Dilek S, Ertunc D, Tok EC, Erdal EM, Aktas A. Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil Steril 2005; 84: 407-12.
138. Christopoulos P, Mastorakos G, Gazouli M, et al. Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact? Gynecol Endocrinol 2010; 2: 698-703.
139. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 4297-300.
140. Villuendas G, Botella-Carretero JI, Roldan B, Sancho J, Escobar-Morreale HF, San Millan JL. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS- 2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod 2005; 20: 3184-91.
141. El Mkadem SA, Lautier C, Macari F, et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-tosevere insulin resistance of women with polycystic ovary syndrome. Diabetes 2001; 50: 2164-2168.
142. Marioli DJ, Koika V, Adonakis GL, et al. No association of the G972S polymorphism of the insulin receptor substrate-1 gene with polycystic ovary syndrome in lean PCOS women with biochemical hyperandrogenemia. Arch Gynecol Obstet 2010; 281: 1045-9.
143. Dravecká I, Lazúrová I, Habalová V. The prevalence of Gly972Arg and C825T polymorphisms in Slovak women with polycystic ovary syndrome and their relation to the metabolic syndrome. Gynecol Endocrinol 2010; 26: 356-60.
144. Witchel SF, Kahsar-Miller M, Aston CE, White C, Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. Fertil Steril 2005; 83: 371-5.
145. Ertunc D, Tok EC, Aktas A, Erdal EM, Dilek S. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. Hum Reprod 2005; 20: 1207-12.
146. Lin TC, Yen JM, Gong KB, et al. Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population-not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med Genet 2006; 7: 36.
147. Sir-Petermann T, Perez-Bravo F, Angel B, Maliqueo M, Calvillan M, Palomino A. G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologia 2001; 44: 1200-1.
148. Ioannidis A, Ikonomi E, Dimou NL, Douma L, Bagos PG. Polymorphisms of the insulin receptor and the insulin receptor substrates genes in polycystic ovary syndrome: a Mendelian randomization meta-analysis. Mol Genet Metab 2010; 99: 174-83.
149. Pappalardo MA, Russo GT, Pedone A, et al. Very high frequency of the polymorphism for the insulin receptor substrate 1 (IRS-1) at codon 972 (glycine972arginine) in Southern Italian women with polycystic ovary syndrome. Horm Metab Res 2010; 42: 575-84.
150. Valdés P, Cerda A, Barrenechea C, Kehr M, Soto C, Salazar LA. No association between common Gly972Arg variant of the insulin receptor substrate-1 and polycystic ovary syndrome in Southern Chilean women. Clin Chim Acta 2008; 390: 63-6.
151. Kim JJ, Choi YM, Hong MA, et al. Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene Met326Ile polymorphism in women with polycystic ovary syndrome. Hum Reprod 2009; 24(5): 1184-90.
152. Zhang F, Liu HW, Fan P, Bai H, Song Q. [The -108 C/T polymorphism in paraoxonase 1 gene in Chinese patients with polycystic ovary syndrome]. Sichuan Da Xue Xue Bao Yi Xue Ban 2011; 42: 24-8.
153. Lenarcik A, Bidzińska-Speichert B, Tworowska-Bardzińska U. The role of chronic inflammation and Leu55Met PON1 polymorphism in the pathogenesis of polycystic ovary syndrome. Gynecol Endocrinol 2010; 26: 673-83.
154. Korhonen S, Heinonen S, Hiltunen M, et al. Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Hum Reprod 2003; 8: 540-3.
155. Gu BH, Baek KH. Pro12Ala and His447His polymorphisms of 101. PPAR-gamma are associated with polycystic ovary syndrome. Reprod Biomed Online 2009; 18: 644-50.
156. Orio F Jr, Matarese G, Di BS, et al. Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 5887-92.
157. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens) 2009; 8: 267-72.
158. Hahn S, Fingerhut A, Khomtsiv U, et al. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2005; 62: 573-9.
159. Koika V, Marioli DJ, Saltamavros AD, et al. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma2 with decreased basic metabolic rate in women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 317-22.
160. Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala 105. polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome. Hormones (Athens) 2009; 8: 267-72.
161. Wang Y, Wu X, Cao Y, Yi L, Fan H, Chen J. Polymorphisms of the peroxisome proliferator-activated receptor-gamma and its coactivator- 1alpha genes in Chinese women with polycystic ovary syndrome. Fertil Steril 2006; 85: 1536-40.
162. Tok EC, Aktas A, Ertunc D, Erdal EM, Dilek S. Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala. Hum Reprod 2005; 20: 1590-5.
163. Yilmaz M, Ergün MA, Karakoç A, Yurtçu E, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor -gamma gene in women with polycystic ovary syndrome. Gynecol Endocrinol 2006; 22: 336-44.
164. Antoine HJ, Pall M, Trader BC, Chen YD, Azziz R, Goodarzi MO. Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertil Steril 2007; 87: 862-9.
165. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene. J Clin Endocrinol Metab 2002; 87: 772-5.
166. Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY. Peroxisome proliferator-activated receptor-gamma and its coactivator- 1alpha gene polymorphisms in Korean women with polycystic ovary syndrome. Gynecol Obstet Invest 2010; 70: 1-7.
167. Alcoser SY, Hara M, Bell GI, Ehrmann DA. Association of the (AU)AT-rich element polymorphism in PPP1R3 with hormonal and metabolic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 2973-6.
168. Xita N, Georgiou I, Tsatsoulis A, Kourtis A, Kukuvitis A, Panidis D. A polymorphism in the resistin gene promoter is associated with body mass index in women with polycystic ovary syndrome. Fertil Steril 2004; 82: 1466-7.
169. Zhang X, Fu L, Zhang Q, et al. Association of TRB3 Q84R polymorphism with polycystic ovary syndrome in Chinese women. Reprod Biol Endocrinol 2011; 9: 46.
170. Li C, Shi Y, You L, Wang L, Chen ZJ. Melatonin Receptor 1A Gene Polymorphism Associated with Polycystic Ovary Syndrome. Gynecol Obstet Inves 2011. [Epub ahead of print] PubMed PMID: 21474908.
171. Zulian E, Sartorato P, Schiavi F et al. The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. Fertil Steril 2005; 84: 1520-1.
172. Karabulut A, Turgut S, Turgut G. Angiotensin converting enzyme gene insertion/deletion polymorphism in patients with polycystic ovary syndrome. Gynecol Endocrinol 2010; 26: 393-8.
173. Celik O, Yesilada E, Hascalik S, et al. Angiotensin-converting enzyme gene polymorphism and risk of insulin resistance in PCOS. Reprod Biomed Online 2010; 20: 492-8.
174. Kaibe M, Takakuwa K, Murakawa H, Ishii K, Tamura M, Tanaka K. Studies on the human leukocyte antigens in patients with polycystic ovary syndrome in a Japanese population-possible susceptibility of HLA-A11 and -DRB1*0403 to patient population with polycystic ovary syndrome. Am J Reprod Immunol 2006; 55: 301-6.
175. Botella-Carretero JI, Luque-Ramirez M, Alvarez-Blasco F, San Millan JL, Escobar-Morreale HF. Mutations in the hereditary hemochromatosis gene are not associated with the increased body iron stores observed in overweight and obese women with polycystic ovary syndrome. Diabetes Care 2006; 29: 2556.
176. Xu N, Taylor KD, Azziz R, Goodarzi MO. Variants in the HMGCoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome. Fertil Steril 2010; 94: 255-60.
177. Kolbus A, Walch K, Nagele F, Wenzl R, Unfried G, Huber JC. Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. J Reprod Immunol 2007; 73: 188-193.
178. Wang B, Zhou S, Wang J et al. Lack of association between interleukin- 1a gene (IL-1a) C (-889) T variant and polycystic ovary syndrome in Chinese women. Endocrine 2009; 35: 198-203.
179. Yang Y, Qiao J, Tang RX, Li MZ. Genotype and haplotype determination of interleukin (IL) 1 beta (g. -511C>T and g. +3954C>T) and IL-1RN in polycystic ovary syndrome. Fertil Steril 2010; 94: 384-6.
180. Mu Y, Liu J, Wang B, et al. Interleukin 1 beta (IL-1β) promoter C [-511] T polymorphism but not C [+3953] T polymorphism is associated with polycystic ovary syndrome. Endocrine 2010; 37: 71-5.
181. Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The -597 G->A and -174 G->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 1134-41.
182. Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-32.
183. Walch K, Grimm C, Zeillinger R, Huber JC, Nagele F, Hefler LA. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril 2004; 81: 1638-41.
184. Vural P, Deǧirmencioǧlu S, Saral NY, Akgül C. Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2010; 150: 61-5.
185. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res 2003; 11: 987-96.
186. Milner CR, Craig JE, Hussey ND, Norman RJ. No association between the -308 polymorphism in the tumor necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries. Mol Hum Reprod 1999; 5: 5-9.
187. Vural P, Küskü-Kiraz Z, Doǧru-Abbasoǧlu S, et al. Vascular endothelial growth factor -2578 A/C, -460 T/C and +405 G/C polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2009; 147: 57-60.
188. Walch K, Nagele F, Zeillinger R, Vytiska-Binstorfer E, Huber JC, Hefler LA. A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the presence of polycystic ovary syndrome in Caucasian women. Fertil Steril 2005; 83: 1565-7.
189. Orio F Jr, Palomba S, Di BS, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 673-9.
190. Thaler CJB, Budiman H, Ruebsamen H, Nagel D, Lohse P. Effects of the common 677C>T mutation of the 5,10- methylenetetrahydrofolate reductase (MTHFR) gene on ovarian responsiveness to recombinant follicle-stimulating hormone. Am J Reprod Immunol 2006; 55: 251-8.
191. Karadeniz M, Erdogan M, Zengi A, et al. Methylenetetrahydrofolate reductase C677T gene polymorphism in Turkish patients with polycystic ovary syndrome. Endocrine 2010; 38: 127-33.
192. Choi SW, Gu BH, Ramakrishna S, Park JM, Baek KH. Association between a single nucleotide polymorphism in MTHFR gene and polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2009; 145: 85-8.
193. Rosen MP, Shen S, McCulloch CE, Rinaudo PF, Cedars MI, Dobson AT. Methylenetetrahydrofolate reductase (MTHFR) is associated with ovarian follicular activity. Fertil Steril 2007; 88: 632-638.
194. Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C. 4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome. J Assist Reprod Genet 2007; 24: 412-8.
195. Sun L, Lv H, Wei W, Zhang D, Guan Y. Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene olymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome. J Endocrinol Invest 2010; 33: 77-82.
196. Kilicci C, Bayram B, Ozkurt M, Onlu H, Erkasap N, Mutlu F. Plasminogen Activator Inhibitor Type-1 Gene 4G/5G Polymorphism and Polycystic Ovary Syndrome. Genet Test Mol Biomarkers 2011; 15: 565-7.
197. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator ihibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol 2004; 150: 793-8.
198. Walch K, Grimm C, Huber JC, Nagele F, Kolbus A, Hefler LA. A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2005; 123: 77-81.
199. Karadeniz M, Erdogan M, Berdeli A, Saygili F, Yilmaz C. 4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome. J Assist Reprod Genet 2007; 24: 412-8.
200. Korhonen S, Romppanen EL, Hiltunen M, et al. Lack of association between C-850T polymorphism of the gene encoding tumor necrosis factor-alpha and polycystic ovary syndrome. Gynecol Endocrinol 2002; 16: 271-4.
201. Milner CR, Craig JE, Hussey ND, Norman RJ. No association between the -308 polymorphism in the tumour necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries. Mol Hum Reprod 1999; 5: 5-9.
202. Peral B, San Millan JL, Castello R, Moghetti P, Escobar-Morreale HF. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 3977-83.
203. Vural P, Küskü-Kiraz Z, Doǧru-Abbasoǧlu S, Cil E, Karadaǧ B, Uysal M. Vascular endothelial growth factor +405 G/C,-460 T/C and -2578 A/C polymorphisms are not associated with insulin resistance in polycystic ovary syndrome. Int J Immunogenet 2010; 37: 239-43.
204. Kjerulff LE, Sanchez-Ramos L, Duffy D. Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis. Am J Obstet Gynecol. 2011; 204(6): 558.e1-e6.
205. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome a hypothesis. J Endocrinol 2002; 174: 1-5.
206. Nestler JE. Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 2000; 24: S71-S73.
207. Gorroochurn P, Hodge SE, Heiman GA, Durner M, Greenberg DA. Non-replication of association studies: 'pseudo-failures' to replicate? Genet Med 2007; 9: 325-331.
208. Legro RS, Barnhart HX, Schlaff WD, et al. Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab 2008; 93: 792-800.
209. Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost 2009; 35: 613-620.
210. Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/ phenotype to thriftiness. Diabetologia 1999; 42: 1367-1374.